Fighting deadly drug resistant bacteria in intestines with new antibiotic

Medical Xpress | January 18, 2019

A new antibiotic developed by a Flinders University researcher is being heralded as a breakthrough in the war against a drug-resistant superbug. Bacteria are winning the fight against antibiotics as they evolve to fight off traditional treatments, threatening decades of advancements in modern medicine, with predictions they will kill over 10 million people by 2050. The scientific development of new, effective and safe antibiotics is crucial in addressing the ever-growing threat posed by drug-resistant bacteria around the world. Clostridium difficile infection (CDI) is a potentially deadly infection in the large intestine most common in people who need to take antibiotics for a long period of time, particularly in Australia's aging population. Dr. Ramiz Boulos, an adjunct research associate at Flinders University and CEO of Boulos & Cooper Pharmaceuticals, says the fact CDI is becoming resistant to traditional antibiotics is alarming and highlights the need to develop more effective treatments.

"Cases of CDI disease are rising and the strains are becoming more lethal. If there is an imbalance in your intestines it can begin to grow and release toxins that attack the lining of the intestines which leads to symptoms," says Dr. Boulos.

Spotlight

Remarkable innovations in the technologies that generate ‘omics data have swiftly created such profound efficiencies that the cost of next-generation sequencing (NGS) has fallen below $1,000 per genome. This has led to the creation of vast amounts of data. The challenge of how to harness this rich information, and from it harvest practicable therapeutics, has been thrust to the forefront of advanced analytics.It is anticipated that in the upcoming decade genomics data will require more computing resources than the data demand from astronomy.

Spotlight

Remarkable innovations in the technologies that generate ‘omics data have swiftly created such profound efficiencies that the cost of next-generation sequencing (NGS) has fallen below $1,000 per genome. This has led to the creation of vast amounts of data. The challenge of how to harness this rich information, and from it harvest practicable therapeutics, has been thrust to the forefront of advanced analytics.It is anticipated that in the upcoming decade genomics data will require more computing resources than the data demand from astronomy.

Related News

CELL AND GENE THERAPY

Thermo Fisher Scientific Announces its Complete Acquisition of Mesa Biotech

Thermo Fisher Scientific | March 01, 2021

Thermo Fisher Scientific Inc. (NYSE: TMO), the world chief in serving science, today reported it has finished its recently declared obtaining of Mesa Biotech, Inc., a secretly held purpose of-care sub-atomic analytic organization. Plateau Biotech has built up the Accula System, a moderate, simple to-utilize, purpose of-care PCR-based testing stage for irresistible infection conclusion. The stage empowers fast, exceptionally precise testing at doctor workplaces, drug stores and different settings, giving outcomes quickly. Past COVID-19 testing, Mesa Biotech's current stage incorporates tests for influenza, respiratory syncytial infection (RSV), and Strep A. "The Accula System complements our existing offerings and immediately provides our clinical customers with more options and flexibility for COVID-19 testing. And, as the point-of-care diagnostic market expands globally, we're well-positioned to deliver a broader menu of tests to meet increasing demand," Stevenson continued. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.

Read More

RESEARCH

AlivaMab Discovery Services is Expanding the Drug Discovery Platform with the Introduction of New Antibody Engineering Department

AlivaMab | May 13, 2021

AlivaMab Discovery Services, LLC ("ADS"), a pioneer in the discovery of superior antibody therapeutics, announced today the formation of its new Antibody Engineering Department, headed by Jonah Rainey, Ph.D. Jonah joins ADS as Vice President of Antibody Engineering, bringing 15 years of experience from Macrogenics Inc. in antibody engineering, discovery, and development, MedImmune, LLC/AstraZeneca PLC, Gritstone Bio, Inc., and, most recently, Immetas Therapeutics, Inc. Jonah's expertise in antibody engineering includes bispecific antibodies, some of which have reached clinical trials, antibody-drug conjugates, Fc modification, in vitro display for antibody discovery and optimization, and structural modeling. “An increasing number of leading pharma and biotechs realize that ADS's pre-existing platform process adds exceptional value to their antibody drug discovery efforts. I am excited to be leading the initiative at ADS to develop new capabilities that will expand the scope and importance that we offer to our clients' drug discovery and development projects. The new Antibody Engineering Department's commitment will help to ensure that ADS delivers the best antibody drug candidates,” said Jonah Rainey, Vice President of Antibody Engineering at AlivaMab Discovery Services. “Today, we significantly expand the ADS discovery platform by adding a new pillar of antibody engineering to our existing pillars of Ablexis' AlivaMab® Mouse, the leading transgenic animal technology for antibody drug discovery, a suite of AMMPD immunization technologies to address even the most challenging targets, a broad sampling of the immune repertoire through function-first high-throughput deep sequencing, and a broad sampling of the immune repertoire through function-first high-throughput sequence analysis. “Jonah's skills and abilities complement and reinforce the ADS team's accumulated decades of experience in discovery and development. We assist our clients in delivering quality medicines to patients quicker by combining team, technology, and partnership.” About AlivaMab Discovery Services AlivaMab Discovery Services is a privately-owned biotechnology company that develops an integrated antibody therapeutic discovery platform that combines innovative technologies and deep expertise to produce superior antibody therapeutics on time. Throughout their careers, the team has completed over 200 discovery projects, yielding several antibody drug candidates in clinical trials. ADS offers a wide range of antibody therapeutic candidates with complex molecular and epitope profiles, functional and kinetic characterization, and superior developability profiles.ADS is trusted by organizations ranging from global pharmaceutical firms to virtual biotechnology companies because of its business model that relies solely on partners instead of developing an internal product pipeline.

Read More

RESEARCH

PostEra announces $260M multi-target strategic AI Lab collaboration with Pfizer

PostEra | January 12, 2022

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, announced the expansion of the company's existing strategic collaboration with Pfizer. The expanded multi-target research program will establish an AI Lab where PostEra and Pfizer jointly advance multiple drug discovery programs with an initial focus in oncology and COVID-19 antiviral therapeutics. The AI Lab will leverage novel machine learning for medicinal chemistry built upon Pfizer's data, and PostEra's pioneering innovations in generative chemistry and synthesis-aware design. PostEra will receive an upfront payment of $13M and is eligible to receive additional milestone payments totalling up to $248M should all milestones be achieved, in addition to tiered royalties on any approved products arising out of the collaboration. The AI Lab will tightly integrate drug discovery with technology development to ensure a continuous feedback loop that refines both the process and predictions from the platform. The vision of the AI Lab is to combine Pfizer's expertise and data with PostEra's technology to advance these drug discovery programs, while also producing an integrated state-of-the-art platform to be deployed across Pfizer's in-house, preclinical drug discovery efforts. "We think the best way to build leading technology is to have its development tightly integrated with live drug discovery programs", said Dr. Alpha Lee, Chief Scientific Officer of PostEra. "We're pleased that we are expanding the existing collaboration to do exactly this and to reap the AI advantage in improving preclinical drug discovery," Aaron Morris, CEO of PostEra "At Pfizer, we believe digital technologies, including artificial intelligence and machine learning, hold great potential to aid the discovery of novel approaches to prevent, cure, and treat disease for patients in need," said Charlotte Allerton, Head of Medicine Design, Pfizer. "We're excited to extend our collaboration with PostEra to further build on our current capabilities." The company today also announced its $24M Series A financing. The new funding will enable PostEra to further expand its partnered drug discovery programs, initiate internal drug discovery programs, as well as further develop its AI-first medicinal chemistry platform. About PostEra PostEra was founded in 2019 and its technology is built on pioneering academic research done by its founding scientists. PostEra's technology addresses some of the key challenges in drug discovery R&D by integrating molecular design with chemical synthesis. PostEra advances small molecule programs through partnerships with biopharma, working on its own internal pipeline, and also offering some of its synthesis technology via its Manifold web platform. PostEra also launched and now helps lead the world's largest open-science drug discovery effort; COVID Moonshot.

Read More